ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.184,94
-0,11%
S&P 500
5.644,45
0,23%
US Dollar vs BRL
5,422
-0,48%
Bitcoin
63.669,30
-1,82%
Brent Oil
83,335
-1,19%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
04/06/200410:00PR Newswire (US)Allos Therapeutics Files Application for European Marketing Approval of RSR13 (efaproxiral)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/06/200411:00PR Newswire (US)Federman & Sherwood Announces That a Securities Class Action Lawsuit Was Filed Against Allos Therapeutics, Inc.NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/06/200410:00PR Newswire (US)Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/05/200410:00PR Newswire (US)Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/05/200413:23PR Newswire (US)Wolf Haldenstein Adler Freeman and Herz LLP Commences Class Action Lawsuit on Behalf of Allos Therapeutics, Inc. ShareholdersNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/05/200418:13PR Newswire (US)Geller Rudman Announces Class Action Lawsuit Against Allos Therapeutics, Inc. on Behalf of InvestorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/05/200417:13PR Newswire (US)Shareholder Class Action Filed Against Allos Therapeutics, Inc. by the Law Firm of Schiffrin & Barroway, LLPNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/05/200419:00PR Newswire (US)Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. Announces Class Action Lawsuit Against Allos Therapeutics, Inc.NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/05/200408:00PR Newswire (US)Allos Therapeutics Reports First Quarter 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/200419:25PR Newswire (US)Allos Therapeutics to Hold Q1 2004 Financial Results Conference Call and Webcast on Thursday, May 6NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/05/200419:04PR Newswire (US)FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases OriginatNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/200418:30PR Newswire (US)Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/03/200416:54PR Newswire (US)Allos NDA to be Reviewed by FDA Advisory CommitteeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/03/200417:17PR Newswire (US)American Stock Exchange to Trade Options on Three SecuritiesNASDAQ:ALTH
05/03/200420:59PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200410:45PR Newswire (US)Reminder - Allos Therapeutics Management Conference CallNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200410:00PR Newswire (US)Allos Begins Phase 3 Study of RSR13 in Women With Brain Metastases From Breast CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200409:00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and Year-End 2003 ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/200309:00PR Newswire (US)Allos Completes New Drug Application for Novel Treatment for Patients With Breast Cancer and Brain MetastasesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200320:30PR Newswire (US)Arizona Cancer Center Investigator Presents Positive Survival and Quality of Life Data From RSR13 Phase 3 StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/11/200310:00PR Newswire (US)Allos Therapeutics Announces RSR13 Phase 3 Results in Patients With Breast Cancer and Brain Metastases Will Be Highlighted at thNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200320:24PR Newswire (US)Allos Therapeutics Completes $12 Million Private PlacementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/11/200315:30PR Newswire (US)Allos Therapeutics Announces Presentation of Phase 1 Results of PDX in Patients With Advanced Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200309:00PR Newswire (US)Allos Therapeutics Announces Presentation of RSR13 Phase 3 Results in Brain Metastases at the Eighth Annual Meeting of the SocieNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/11/200317:00PR Newswire (US)RSR13 Investigator Presented With National Tumor Foundation Research Award At Society for Neuro-Oncology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/11/200310:45PR Newswire (US)Reminder - Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the WebNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/11/200309:00PR Newswire (US)Allos Therapeutics Reports Third Quarter 2003 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200310:45PR Newswire (US)Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the WebNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

NASDAQ
BOKF
BOK Financial
TSXV
ISD
iSign Media Solutions
LSE
BKY
Berkeley Energia
LSE
TOPE
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados